Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Cost of Revenue (2023 - 2025)

Krystal Biotech's Cost of Revenue history spans 3 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 33.22% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $23.0 million, up 14.89%, while the annual FY2025 figure was $23.0 million, 14.89% up from the prior year.
  • Cost of Revenue for Q4 2025 was $6.6 million at Krystal Biotech, up from $4.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $7.2 million in Q2 2025 and bottomed at $223000.0 in Q3 2023.
  • The 3-year median for Cost of Revenue is $5.0 million (2024), against an average of $4.6 million.
  • The largest annual shift saw Cost of Revenue soared 2897.31% in 2024 before it plummeted 36.22% in 2025.
  • A 3-year view of Cost of Revenue shows it stood at $2.9 million in 2023, then skyrocketed by 72.38% to $4.9 million in 2024, then skyrocketed by 33.22% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cost of Revenue are $6.6 million (Q4 2025), $4.3 million (Q3 2025), and $7.2 million (Q2 2025).